Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
作者： Brian I Rini , Bohuslav Melichar , Takeshi Ueda , Viktor Grünwald , Mayer N Fishman
DOI: 10.1016/S1470-2045(13)70464-9
关键词:
摘要: Background Population pharmacokinetic data suggest axitinib plasma exposure correlates with efficacy in metastatic renal-cell carcinoma. Axitinib dose titration might optimise …
elsevier.com
sci-hub.se 参考文章(33)
A TROTTI, A COLEVAS, A SETSER, V RUSCH, D JAQUES, V BUDACH, C LANGER, B MURPHY, R CUMBERLIN, C COLEMAN, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology. ,vol. 13, pp. 176- 181 ,(2003) , 10.1016/S1053-4296(03)00031-6
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
Yazdi K. Pithavala, Ying Chen, Melvin Toh, Paulina Selaru, Robert R. LaBadie, May Garrett, Brian Hee, Janessa Mount, Grace Ni, Karen J. Klamerus, Michael A. Tortorici, Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers Cancer Chemotherapy and Pharmacology. ,vol. 70, pp. 103- 112 ,(2012) , 10.1007/S00280-012-1888-9
Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J Motzer, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial The Lancet. ,vol. 378, pp. 1931- 1939 ,(2011) , 10.1016/S0140-6736(11)61613-9
Larry Rubinstein, John Crowley, Percy Ivy, Michael LeBlanc, Dan Sargent, Randomized Phase II Designs Clinical Cancer Research. ,vol. 15, pp. 1883- 1890 ,(2009) , 10.1158/1078-0432.CCR-08-2031
A.M. Molina, X. Lin, B. Korytowsky, E. Matczak, M.J. Lechuga, R. Wiltshire, R.J. Motzer, Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. European Journal of Cancer. ,vol. 50, pp. 351- 358 ,(2014) , 10.1016/J.EJCA.2013.08.021
Y. Chen, J. Jiang, J. Zhang, M.A. Tortorici, Y.K. Pithavala, L. Lu, G. Ni, P. Hu, A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. principles and practice of constraint programming. ,vol. 49, pp. 679- 687 ,(2011) , 10.5414/CP201570
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza, Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma European Journal of Cancer. ,vol. 47, pp. 2592- 2602 ,(2011) , 10.1016/J.EJCA.2011.07.014
Hope S. Rugo, Roy S. Herbst, Glenn Liu, John W. Park, Merrill S. Kies, Heidi M. Steinfeldt, Yazdi K. Pithavala, Steven D. Reich, James L. Freddo, George Wilding, Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results Journal of Clinical Oncology. ,vol. 23, pp. 5474- 5483 ,(2005) , 10.1200/JCO.2005.04.192
Roger B. Cohen, Stéphane Oudard, Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Investigational New Drugs. ,vol. 30, pp. 2066- 2079 ,(2012) , 10.1007/S10637-012-9796-8